Timing is everything: The importance of patient-reported outcome assessment frequency when characterizing symptomatic adverse events.

This analysis demonstrates that more frequent assessment of patient-reported symptomatic adverse events will lead to improved detection, and therefore a more complete understanding of the tolerability of experimental anti-cancer therapies.